Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 15 studies | 29% ± 15% | |
Mueller cell | 6 studies | 37% ± 9% | |
connective tissue cell | 3 studies | 22% ± 4% |
Insufficient scRNA-seq data for expression of FAP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 98% | 881.64 | 450 / 459 | 95% | 21.84 | 1062 / 1118 |
lung | 89% | 512.08 | 517 / 578 | 87% | 9.39 | 1001 / 1155 |
uterus | 98% | 2480.74 | 167 / 170 | 59% | 6.13 | 270 / 459 |
skin | 81% | 2792.37 | 1469 / 1809 | 68% | 5.91 | 319 / 472 |
esophagus | 79% | 341.47 | 1141 / 1445 | 68% | 7.24 | 124 / 183 |
pancreas | 45% | 125.43 | 147 / 328 | 91% | 18.40 | 162 / 178 |
intestine | 65% | 282.35 | 628 / 966 | 61% | 6.45 | 321 / 527 |
thymus | 87% | 366.69 | 569 / 653 | 34% | 2.19 | 208 / 605 |
bladder | 52% | 176.10 | 11 / 21 | 61% | 6.06 | 306 / 504 |
stomach | 29% | 92.19 | 103 / 359 | 70% | 6.95 | 200 / 286 |
blood vessel | 99% | 1361.98 | 1316 / 1335 | 0% | 0 | 0 / 0 |
adipose | 97% | 723.28 | 1163 / 1204 | 0% | 0 | 0 / 0 |
ovary | 47% | 155.51 | 84 / 180 | 45% | 4.37 | 195 / 430 |
prostate | 49% | 146.17 | 120 / 245 | 35% | 1.53 | 175 / 502 |
tonsil | 0% | 0 | 0 / 0 | 53% | 3.84 | 24 / 45 |
muscle | 49% | 129.32 | 393 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 48% | 3.04 | 14 / 29 |
kidney | 18% | 72.25 | 16 / 89 | 29% | 1.66 | 265 / 901 |
heart | 37% | 142.07 | 318 / 861 | 0% | 0 | 0 / 0 |
brain | 5% | 8.62 | 136 / 2642 | 17% | 1.04 | 123 / 705 |
liver | 2% | 5.98 | 4 / 226 | 19% | 0.98 | 77 / 406 |
adrenal gland | 0% | 1.06 | 1 / 258 | 16% | 1.20 | 36 / 230 |
eye | 0% | 0 | 0 / 0 | 10% | 0.87 | 8 / 80 |
spleen | 7% | 15.15 | 17 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001525 | Biological process | angiogenesis |
GO_0051917 | Biological process | regulation of fibrinolysis |
GO_1902362 | Biological process | melanocyte apoptotic process |
GO_0007155 | Biological process | cell adhesion |
GO_0060244 | Biological process | negative regulation of cell proliferation involved in contact inhibition |
GO_0043542 | Biological process | endothelial cell migration |
GO_0006508 | Biological process | proteolysis |
GO_0010710 | Biological process | regulation of collagen catabolic process |
GO_0051603 | Biological process | proteolysis involved in protein catabolic process |
GO_1903054 | Biological process | negative regulation of extracellular matrix organization |
GO_0097325 | Biological process | melanocyte proliferation |
GO_0010716 | Biological process | negative regulation of extracellular matrix disassembly |
GO_1900119 | Biological process | positive regulation of execution phase of apoptosis |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0032587 | Cellular component | ruffle membrane |
GO_0045178 | Cellular component | basal part of cell |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005925 | Cellular component | focal adhesion |
GO_0009986 | Cellular component | cell surface |
GO_0031258 | Cellular component | lamellipodium membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_1905368 | Cellular component | peptidase complex |
GO_0030027 | Cellular component | lamellipodium |
GO_0045177 | Cellular component | apical part of cell |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0008233 | Molecular function | peptidase activity |
GO_0008239 | Molecular function | dipeptidyl-peptidase activity |
GO_0004175 | Molecular function | endopeptidase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005178 | Molecular function | integrin binding |
GO_0002020 | Molecular function | protease binding |
GO_0008236 | Molecular function | serine-type peptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | FAP |
Protein name | Fibroblast activation protein alpha Prolyl endopeptidase FAP (EC 3.4.21.26) (170 kDa melanoma membrane-bound gelatinase) (Dipeptidyl peptidase FAP) (EC 3.4.14.5) (Fibroblast activation protein alpha) (FAPalpha) (Gelatine degradation protease FAP) (EC 3.4.21.-) (Integral membrane serine protease) (Post-proline cleaving enzyme) (Serine integral membrane protease) (SIMP) (Surface-expressed protease) (Seprase) [Cleaved into: Antiplasmin-cleaving enzyme FAP, soluble form (APCE) (EC 3.4.14.5) (EC 3.4.21.-) (EC 3.4.21.26)] Fibroblast activation protein alpha (cDNA FLJ60298, highly similar to Seprase) |
Synonyms | |
Description | FUNCTION: Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2 . Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vitronectin, tenascin, laminin, fibronectin, fibrin or casein . Also has dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro . Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB) . The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner. . |
Accessions | H0YG61 H7C4D9 B4DLR2 C9J131 ENST00000447386.5 ENST00000188790.9 [Q12884-1] Q12884 F8WF29 ENST00000422436.5 ENST00000443424.5 ENST00000462608.5 ENST00000450031.2 |